KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Pacira BioSciences (PCRX) Leases (2019 - 2025)

Pacira BioSciences has reported Leases over the past 7 years, most recently at $41.8 million for Q4 2025.

  • Quarterly results put Leases at $41.8 million for Q4 2025, down 15.13% from a year ago — trailing twelve months through Dec 2025 was $41.8 million (down 15.13% YoY), and the annual figure for FY2025 was $41.8 million, down 15.13%.
  • Leases for Q4 2025 was $41.8 million at Pacira BioSciences, down from $44.3 million in the prior quarter.
  • Over the last five years, Leases for PCRX hit a ceiling of $76.4 million in Q4 2021 and a floor of $41.8 million in Q4 2025.
  • Median Leases over the past 5 years was $64.6 million (2023), compared with a mean of $61.7 million.
  • Biggest five-year swings in Leases: surged 93.78% in 2021 and later dropped 19.33% in 2024.
  • Pacira BioSciences' Leases stood at $76.4 million in 2021, then dropped by 7.24% to $70.9 million in 2022, then decreased by 13.91% to $61.0 million in 2023, then dropped by 19.33% to $49.2 million in 2024, then decreased by 15.13% to $41.8 million in 2025.
  • The last three reported values for Leases were $41.8 million (Q4 2025), $44.3 million (Q3 2025), and $46.5 million (Q2 2025) per Business Quant data.